NCT01725685 - To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 8, 2012

Primary Completion Date

January 2, 2013

Study Completion Date

January 2, 2013

Conditions

Asthma

Interventions

DRUG

FF 400 mcg

FF will be available as 100 mcg strength administered as 4 inhalations from a DPI

DRUG

UMEC 500 mcg

UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI

DRUG

FF/UMEC 400/500 mcg

FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI

Trial Locations (1)

GSK Investigational Site, Baltimore